TCM
Tang Capital Management Portfolio holdings
AUM
$1.98B
This Quarter Return
+16.47%
1 Year Return
+21.62%
3 Year Return
+290.69%
5 Year Return
+284.46%
10 Year Return
+928.34%
AUM
$1.4B
AUM Growth
+$1.4B
(+43%)
Cap. Flow
+$313M
Cap. Flow
% of AUM
22.32%
Top 10 Holdings %
Top 10 Hldgs %
35.88%
Holding
163
New
35
Increased
43
Reduced
14
Closed
8
Top Buys
| 1 |
Aurinia Pharmaceuticals
AUPH
|
$32.6M |
| 2 |
BioNTech
BNTX
|
$32.1M |
| 3 |
Relay Therapeutics
RLAY
|
$25.3M |
| 4 |
ITOS
iTeos Therapeutics
ITOS
|
$24.6M |
| 5 |
Immunocore
IMCR
|
$21.8M |
Top Sells
| 1 |
Eli Lilly
LLY
|
$24.4M |
| 2 |
Dynavax Technologies
DVAX
|
$6.68M |
| 3 |
Beam Therapeutics
BEAM
|
$2.45M |
| 4 |
Inhibrx
INBX
|
$2.37M |
| 5 |
CRISPR Therapeutics
CRSP
|
$2.35M |
Sector Composition
| 1 | Healthcare | 95.59% |
| 2 | Technology | 1.47% |
| 3 | Communication Services | 1.22% |
| 4 | Real Estate | 0.34% |
| 5 | Financials | 0.3% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
151
Lexicon Pharmaceuticals
LXRX
$392M
| $157K | 0.01% |
+100,000
| New | +$157K |
|
152
Ford
F
$46.2B
| $135K | 0.01% |
12,773
| – | – |
|
153
LAVA Therapeutics
LVTX
$41.3M
| $88.1K | 0.01% |
53,101
+47,992
| +939% | +$79.7K |
|
|
ALLK
154
DELISTED
Allakos
ALLK
| $29.6K | ﹤0.01% |
+45,262
| New | +$29.6K |
|
|
155
Inhibrx
INBX
$403M
| – | – |
-167,500
| Closed | -$2.37M |
|
|
156
Eli Lilly
LLY
$661B
| – | – |
-27,000
| Closed | -$24.4M |
|
|
MOLN
157
Molecular Partners
MOLN
$139M
| – | – |
-2,500
| Closed | -$18.1K |
|
158
Quince Therapeutics
QNCX
$86.5M
| – | – |
-1,500,000
| Closed | -$1.13M |
|
|
ADAP
159
Adaptimmune Therapeutics
ADAP
$13.9M
| – | – |
-1,743,619
| Closed | -$1.7M |
|
160
Aligos Therapeutics
ALGS
$75.1M
| – | – |
-66,000
| Closed | -$578K |
|
161
Douglas Emmett
DEI
$2.7B
| – | – |
-171,138
| Closed | -$2.28M |
|
162
Journey Medical
DERM
$187M
| – | – |
-148,322
| Closed | -$837K |
|